Akebia Therapeutics, Inc.
AKBANext catalyst
Praliciguat
Focal Segmental Glomerulosclerosis
Get an email about AKBA's next catalysts
Track Akebia Therapeutics (AKBA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
AKBA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.03 | FQ end Sep/2026 | Call: tbd
Praliciguat Phase 2 Est. Readout
Primary completion for Praliciguat trial (NCT07268638) in Focal Segmental Glomerulosclerosis
SourcePraliciguat (Part A) Phase 2 Est. Readout
Estimated primary completion for Praliciguat (Part A) trial (NCT07268638) in Focal Segmental Glomerulosclerosis. Topline data typically follows completion by weeks to months.
SourceHow AKBA's past catalysts played out
Market Overview
Stock performance and key metrics
Ferric Citrate 1 GM Oral Tablet
Anemia, Iron Deficiency
Erythropoiesis-Stimulating Agent (ESA)
Anemia of Chronic Kidney Disease
Erythropoiesis Stimulating Agent
Anemia of Chronic Kidney Disease
Vadadustat
Anemia
Mircera®
Anemia Associated With Chronic Kidney Disease (CKD)
Darbepoetin alfa
Anemia
Vadadustat TIW
Anemia
AKB-6548
Anemia
Praliciguat (Part A)
Focal Segmental Glomerulosclerosis
Epoetin Alfa
Anemia
IW-1973
Heart Failure With Preserved Ejection Fraction
Praliciguat
Focal Segmental Glomerulosclerosis
ADX-097
IgA Nephropathy
Praliciguat (Part B)
Focal Segmental Glomerulosclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ferric Citrate 1 GM Oral Tablet | Phase 3 | Anemia, Iron Deficiency | - | - |
Erythropoiesis-Stimulating Agent (ESA) | Phase 3 | Anemia of Chronic Kidney Disease | - | - |
Erythropoiesis Stimulating Agent | Phase 3 | Anemia of Chronic Kidney Disease | - | - |
Vadadustat | Phase 3 | Anemia | - | - |
Mircera® | Phase 3 | Anemia Associated With Chronic Kidney Disease (CKD) | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
Vadadustat TIW | Phase 2 | Anemia | - | - |
AKB-6548 | Phase 2 | Anemia | - | - |
Praliciguat (Part A) | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
Epoetin Alfa | Phase 2 | Anemia | - | - |
IW-1973 | Phase 2 | Heart Failure With Preserved Ejection Fraction | - | - |
Praliciguat | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
ADX-097 | Phase 2 | IgA Nephropathy | - | - |
Praliciguat (Part B) | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
Frequently asked questions
What is in Akebia Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Akebia Therapeutics, Inc.'s (AKBA) pipeline across Phase 3, Phase 2. Its lead program is Darbepoetin alfa (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Akebia Therapeutics, Inc.'s next FDA catalyst?→
Akebia Therapeutics, Inc.'s (AKBA) next tracked catalyst is a Phase 2 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AKBA biotech catalysts?→
Add AKBA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Akebia Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.